Business
Discovery and a Principal Investigator of NIH- SBIR grants while tenured at Intrinsic Bioprobes, Inc (based in Tempe, AZ). He has a PhD in Bio- Analytical Chemistry from the Department of Chemistry at Arizona State University.
Dr Stephen Naylor is a Co-Founder, COO and Board Chairman of iMetabolic Biopharma Corporation. He is also the Co-Founder, CEO and Board Chairman of ReNeuroGen LLC, a virtual pharmaceutical company developing therapies for the treatment of neurological diseases. In addition, he is the Founder, Chairman and CEO of MaiHealth Inc, a systems/network biology level diagnostics company in the health/wellness and precision medicine sector. He was also part of the scientific founder team of Beyond Genomics Inc and in his capacity as CTO helped build the world’s first systems biology platform. He serves as an Advisory Board Member of CureHunter Inc, a computational biology drug discovery company, and as a business adviser to the not-for-profit Cures Within Reach. In the past he has held pro- fessorial chairs in Biochemistry & Molecular Biology; Pharmacology; Clinical Pharmacology and Biomedical Engineering, all at Mayo Clinic in Rochester, MN, USA. He holds a PhD from the University of Cambridge (UK), and undertook a NIH-funded fellowship at MIT located in the ‘other’ Cambridge, USA. Address correspondence to him at
snaylor@imbiopharma.com.
Continued from page 42
10 Carreyou, J. Bad Blood: Secrets and Lies in a Silicon Valley Startup. Alfred A. Knopf Publishing. (2018). 11 Servick, K. This Mysterious $2 Billion Biotech is Revealing the Secrets Behind its New Drugs and Vaccines. Science.
http://www.sciencemag.org/ne ws/2017/02/mysterious-2- billion-biotech-revealing- secrets-behind-its-new-drugs- and-vaccines . February 1st (2017). 12 Moderna Press Release. Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA- 1440, Induces High Levels of Immunogenicity.
https://www.modernatx.com/n ewsroom/press-releases/ moderna-announces-positive- interim-phase-1-clinical-data April 27th (2017). 13 Oakes, B and Amer, Y. One of Biotech’s Biggest Investors Says the Industry Must be Unreasonable. WBUR Website- Bioboom. http://www.wbur. org/commonhealth/2018/06/07 /noubar-afeyan-interview June 7 (2018). 14 Moderna Website.
https://www.modernatx.com/pi peline Visited September 23rd, (2018).
Drug Discovery World Fall 2018
43
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
